Detox Dox Mathis P. C. Las Vegas, Nevada, United States
Session Description: Workshop Description
This presentation describes a protocol to safely transition opioid use disorder patients to long acting formulations of buprenorphine. Long acting formulations of buprenorphine provides significant advantages to the use of sublingual formulations. Some of these advantages include that the buprenorphine formulation does not contain naloxone, which if absorbed will cause acute opioid withdrawal, and lead to loss of control regarding the use of opiates and other potentially misused drugs, and will improve compliance, resulting in more consistent blood levels.
By learning how to transition patients to the long acting Buprenorphine safely, clinicians will find detoxing their patients to be increasingly easier and safer without the fear of life threatening situations that often accompany withdrawal. Additionally, the patients will find this form of detox more comfortable and as such, the potential exists for significant decrease in relapse therefore leading to a higher success rate in treating patients with addiction. In the long run, this could lead to better med adherence with other disorders, decrease hospitalizations from relapse, cost savings with less laboratory tests and overall safety for both the patient and their family.
Learning Objectives:
After this activity participants should be able to
Upon completion, participant will be able to implement a safe induction, and stabilization protocol to transition patients to a long acting buprenorphine formulation for maintenance treatment.
Upon completion, participant will be able to effectively monitor the patients safe use of buprenorphine with guidelines for frequency of drug testing, and checking state prescription monitoring sites.
Upon completion, participant will be able to follow guidelines on how to take patients off buprenorphine.